Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At-Risk Launches: Three Cases May Determine How Damages Are Calculated

Executive Summary

How risky are at-risk launches of generic products?

You may also be interested in...



ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump

Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.

A Closer Look: Sun’s Settlement With Pfizer May Cloud Its Ability For Large Buyouts

With a large chunk of its cash reserves spent to settle the Protonix patent case, India’s Sun Pharma may no longer be in position to follow its inorganic growth plans.

Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel